Key result
Oral anticoagulant monotherapy and direct oral anticoagulant-based dual therapy following PCI offer advantages in patients with atrial fibrillation and chronic ischemic heart disease.
Why the study?
What is the optimal antithrombotic therapy strategy in patients with atrial fibrillation and chronic ischemic heart disease?
What is the optimal antithrombotic therapy strategy in patients with atrial fibrillation and chronic ischemic heart disease?
Answers are grounded in this paper and cite their sources.
This review highlights the modern evidence base supporting oral anticoagulant monotherapy for stable patients with AF and IHD, and dual antithrombotic therapy following PCI.
The review is devoted to the use of antithrombotic therapy in patients with atrial fibrillation (AF) and chronic ischemic heart disease (IHD). We discuss data of international registries, meta-analyses assessing possibilities of the use of oral anticoagulants for secondary prevention of IHD. We present here results of randomized and observational clinical studies demonstrating advantages of prescription of monotherapy with oral anticoagulants (OAC) in combination of AF and chronic IHD. Modern evidence base of advantages of dual antithrombotic therapy with the use of direct OAC following percutaneous coronary intervention is also presented.
No takes yet. Share an insight, caveat, or question.
Rychkov et al. (2019) conducted a review in Atrial fibrillation and chronic ischemic heart disease. Antithrombotic therapy (oral anticoagulants) was evaluated. Oral anticoagulant monotherapy and direct oral anticoagulant-based dual therapy following PCI offer advantages in patients with atrial fibrillation and chronic ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: